Implementation and first outcomes of a novel standard operating procedure for preprocedural transoesophageal echocardiography screening in course of atrial arrhythmia ablation
Europace · 2023
DOI: 10.1093/europace/euad279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2023. Verfasst von Sebastian Dittrich und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrophysiology, Heart Center, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. Hauptthemen laut MEDLINE: Atrial Fibrillation, Heart Diseases, Thrombosis, Catheter Ablation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Preprocedural transoesophageal echocardiography (TEE) screening for left atrial (LA) thrombi is the standard of care in many centres performing atrial fibrillation (AF) ablation. However, TEE imposes procedural risks for patients and is often challenging to implement in daily practice, besides causing patient discomfort. At our centre, a novel standard operating procedure (SOP) was implemented, aiming to identify patients that can be exempt from TEE screening. We aimed to assess whether this screening approach may reduce preprocedural TEEs without imposing patients of higher risks for cerebrovascular events (CVEs). Methods and results Data of 1874 consecutive patients treated by catheter ablation of LA arrhythmias between 2018 and 2022 were retrospectively analysed. A cohort of 937 patients, where decision to perform TEE screening was based on a new SOP (considering rhythm at admission, CHA2DS2-VASc score, and sufficient anticoagulation), was compared to a matched cohort receiving TEE before every procedure. Number of performed TEEs and incidences of CVEs were compared. Implementation of the new SOP led to a 67% reduction in TEEs performed (old SOP: 933 vs. new SOP: 305). No significant differences between the groups were detected regarding transitory ischaemic attack (old SOP: 5 vs. new SOP: 3; P = 0.48) and stroke (no events). No solid thrombi were detected during TEE screening.
Conclusion
The number of preprocedural screening TEEs before AF ablation procedures can be safely reduced by applying risk stratification based on rhythm at admission and CHA2DS2-VASc score, if anticoagulation was performed properly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Electrophysiology, Heart Center, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
ORCID-Profile: Sebastian Dittrich, Fehmi Kece, Cornelia Scheurlen, Jan-Hendrik van den Bruck, Karlo Filipovic, Jonas Wörmann, Susanne Erlhöfer, Friederike Pavel, Jan-Hendrik Schipper, Arian Sultan, Jakob Lüker, Daniel Steven
Zitieren
APA
Dittrich, S., Kece, F., Scheurlen, C., van den Bruck, J. H., Filipovic, K., Wörmann, J., Erlhöfer, S., Pavel, F., Schipper, J. H., Sultan, A., Lüker, J., & Steven, D. (2023). Implementation and first outcomes of a novel standard operating procedure for preprocedural transoesophageal echocardiography screening in course of atrial arrhythmia ablation. Europace. https://doi.org/10.1093/europace/euad279
Vancouver
Dittrich S, Kece F, Scheurlen C, van den Bruck JH, Filipovic K, Wörmann J, et al. Implementation and first outcomes of a novel standard operating procedure for preprocedural transoesophageal echocardiography screening in course of atrial arrhythmia ablation. Europace. 2023. doi:10.1093/europace/euad279
BibTeX
@article{Dittrich2023,
author = {Dittrich, Sebastian and Kece, Fehmi and Scheurlen, Cornelia and van den Bruck, Jan-Hendrik and Filipovic, Karlo and Wörmann, Jonas and Erlhöfer, Susanne and Pavel, Friederike and Schipper, Jan-Hendrik and Sultan, Arian and Lüker, Jakob and Steven, Daniel},
title = {Implementation and first outcomes of a novel standard operating procedure for preprocedural transoesophageal echocardiography screening in course of atrial arrhythmia ablation},
journal = {Europace},
year = {2023},
doi = {10.1093/europace/euad279}
}
EUVIMED